India’s startup funding market is producing three very different stories this week. Superhealth is changing the investor mix of its planned hospital-expansion round. Online pharmacy PlatinumRx is reportedly in talks for a large fundraise. And entrepreneur Manav Garg is preparing a new artificial-intelligence commerce venture with possible backing from Sachin Bansal.

The important detail is that not all three deals are complete. Superhealth has partial commitments, while PlatinumRx and Garg’s new venture are still in discussions.

Superhealth replaces Ronnie Screwvala with TechU Ventures

Bengaluru-based Superhealth was founded in 2024 by Varun Dubey. The company is building a hospital network based on fixed prices for medical procedures and a zero-commission model for doctors.

This means a patient should know the procedure cost upfront instead of facing a bill that changes through multiple add-ons. Superhealth also uses its in-house SuperOS platform to manage tasks ranging from consultations and diagnostics to surgery scheduling and discharge.

The startup’s proposed Rs. 100 crore fundraise has changed direction. Ronnie Screwvala is no longer participating after the two sides reportedly failed to agree on terms. US-based TechU Ventures and high-net-worth individuals have committed around Rs. 50 crore so far, while Superhealth continues talks for the remaining amount as per Moneycontrol reports.

The funding, if fully closed, would support Superhealth’s hospital-network expansion. Its competitors include Apollo Hospitals, Narayana Health, Manipal Hospitals and newer healthcare providers trying to make treatment pricing more transparent.

PlatinumRx discusses a $32 million round

PlatinumRx is an online pharmacy founded in 2023 by Ashutosh Pandey and Piyush Kumar. Its focus is affordable medicine delivery, especially by helping customers find lower-cost substitutes where appropriate.

The Bengaluru-based company is reportedly in talks to raise about $32 million, or more than Rs. 300 crore, in a round led by Sofina. The proposed deal could value PlatinumRx between $150 million and $200 million, according to Inc42.

However, this is not a closed funding announcement. The investors, valuation and final deal size could change before the transaction is completed.

PlatinumRx previously raised $6 million in Series A funding in 2025. That funding was intended for supply-chain strengthening, fulfilment expansion and product development. Its current aim remains the same: make quality medicines easier to access at lower prices. Company says it operates licensed pharmacy premises and delivers across India.

The company competes with Tata 1mg, PharmEasy, Netmeds, Apollo 24|7 and fellow affordable-medicine platform Plazza. In this category, customer trust, prescription compliance and dependable delivery are just as important as discounts.

Manav Garg’s agentic commerce startup

Manav Garg, who recently stepped down as executive chairman of Emergent, is reportedly launching an agentic commerce startup. Sachin Bansal, the co-founder of Flipkart and Navi, is said to be discussing an investment of $20 million to $30 million.

The startup has not yet been formally announced, and its product details remain limited. Sources told Moneycontrol that Garg is seeking a much larger initial round of around $100 million.

Agentic commerce means using AI software that can help users find, compare and possibly buy products. For example, instead of opening five shopping apps, a user might ask an AI assistant to find a phone within a budget, compare offers and guide the purchase.

This emerging space will face competition from Amazon, Google, OpenAI-powered shopping tools and established ecommerce platforms. The challenge will be building consumer trust, reliable product data and safe payment experiences.

A delivery-first pizza brand, a printed-menswear label, a sports retail platform and a rehabilitation-tech company may appear unrelated. Yet, their latest funding moves point to a familiar investor theme which is businesses solving everyday Indian needs with a sharper product and a clear plan to grow.

Hundo Pizza has raised Rs. 7.5 crore in its first institutional funding round led by Titan Capital. At the same time, QB MEN, PlayBlue and Rymo Technologies have also drawn investor attention at different early stages.

Hundo Pizza plans to grow beyond Mumbai

Mumbai-based Hundo Pizza was founded in 2020 by Kabir Moorjani and Ronak Rajani. It runs a delivery-first model, serving hand-tossed pizzas, garlic bread and pasta instead of operating a traditional dine-in restaurant.

The company’s Rs. 7.5 crore round was led by Titan Capital, with participation from Indian Silicon Valley Capital, Ankur Rangnekar, Akshay Rangnekar and Haresh Chawla. Reports showing that the company plans to strengthen production, technology and its team while preparing to enter a new city.

A major part of the plan is a 5,000 sq. ft. central kitchen in Andheri East. This can help the brand prepare dough and key ingredients in one controlled location, making it easier to maintain the same taste across outlets. Hundo also plans to use connected systems to track equipment such as ovens and refrigeration units.

Its biggest rivals include Domino’s, La Pino’z Pizza, Pizza Hut and independent premium pizza brands. Hundo’s challenge is simple: keep quality consistent while growing fast enough to build repeat orders in a new city.

QB MEN bets on distinctive everyday fashion

Jaipur-based QB MEN has secured a pre-seed round led by BeyondSeed, with Rajkot Ventures and Prajay Advisors joining the investment. The round size has not been disclosed.

Founded in 2020 by Yash Bothra, QB MEN sells printed shirts, kurtas, jackets and co-ord sets that mix Indian-inspired prints with modern cuts. The company follows a smaller-batch approach, using customer response before increasing production. Report identifies the brand as a Jaipur D2C menswear startup.

The new funding will focus on content, customer experience, brand-building, retention marketing and wider distribution. Its competition comes from D2C fashion labels, marketplace sellers and established menswear brands. For QB MEN, the real task is turning first-time buyers into regular customers.

PlayBlue wants to organize sports retail

Bengaluru-based PlayBlue was founded in 2025 by Satyam Trivedi and Jayam Vora. The company raised a $2.7 million seed round earlier this year from Centre Court Capital, MIXI Global and WEH Ventures to build its sports retail platform and launch flagship stores.

The business recently added cricketer KL Rahul as an investor and brand ambassador. PlayBlue plans to combine equipment, footwear, apparel, testing services and community spaces under one roof. Its competitors include Decathlon, Sports Station and online sports sellers.

Rymo aims to make rehabilitation more accessible

Mumbai-based Rymo Technologies, founded in 2020 by Chirag Shah and Abhishek Rai, develops robotic and AI-assisted rehabilitation tools for patients recovering from neurological and orthopaedic conditions.

Early-stage fund 1Crowd has added Rymo to its healthcare portfolio. The investment amount was not disclosed. Rymo’s products aim to help clinics provide technology-supported physiotherapy without relying entirely on expensive imported equipment.

Docterz, a healthtech company for doctors and clinics, has received backing from people who already use its platform. At the other end of the market, One Planet Partners and Japan’s Sumitomo Mitsui Trust Bank are setting up a large private-equity fund for growing Indian businesses.

One story is about a startup raising a relatively small round with strong customer support. The other is about creating a much larger pool of money for companies that are ready to scale.

Docterz gets backing from doctors who use its platform

Healthtech startup Docterz has raised Rs. 5 crore from around 35 investors. Nearly 60 percent of the money came from doctors who already use the company’s services. The round also included SUGAR Cosmetics co-founder Vineeta Singh and CaratLane co-founder Avnish Anand.

Docterz was founded more than a decade ago by Dr. Atish Laddad. Its technology helps doctors and clinics manage day-to-day work, including patient appointments, digital medical records, billing, vaccine inventory, queue management, and communication with patients.

As per ET, the company says its platform supports more than 5,000 doctors across India. That makes the funding round notable because some of its own users have chosen to invest in the business. A doctor who uses the platform every day may understand its value more clearly than an outside investor looking only at numbers.

For a small clinic, software like Docterz can reduce paperwork and help staff spend less time coordinating appointments or maintaining records. A doctor can also use it to track follow-ups, manage billing, and communicate with patients in one place.

The startup plans to use the capital for organic expansion, possible acquisitions, and practical AI features for doctors. It also wants to reach more independent practitioners, clinics, and healthcare organisations.

Docterz operates in a competitive market that includes clinic-management software companies, appointment-booking platforms, and teleconsultation services such as Practo. Its advantage may lie in being built around the daily working needs of doctors rather than only patient discovery.

One Planet Partners aims for bigger growth investments

Mumbai-based One Planet Partners has launched its first private-equity fund in partnership with Sumitomo Mitsui Trust Bank, commonly known as SMTB. The fund is targeting more than Rs. 3,000 crore.

It is important to understand the difference between a fund target and money already available. The Rs. 3,000 crore figure is the intended size of the fund, not the confirmed amount raised so far. The firm plans to achieve its first close by mid-2027.

Founded in 2024, One Planet Partners was established by Mukund Rajan, Bobby Pauly, Mrinalini Mirchandani, and Sheetal Thakkar. SMTB has made a strategic investment in the firm and is also anchoring the fund.

As reported, the fund will focus on Indian mid-market businesses that can benefit from energy transition, new mobility, and manufacturing growth. It intends to invest between Rs. 100 crore and Rs. 500 crore in companies with annual revenue ranging from Rs. 200 crore to Rs. 2,000 crore.

This is growth capital, not early-stage startup funding. For example, an electric mobility company with a proven product and a growing customer base may need capital to expand manufacturing, build charging infrastructure, or enter new cities. A private-equity fund can support that next phase.

One Planet Partners has already participated in the Series C round of Bengaluru-based electric mobility company Yulu.

Indian startup funding is no longer limited to apps, fintech and food delivery. The latest funding updates show money flowing into defence manufacturing, healthcare delivery, clean energy hardware and preventive wellness.

Hughes Precision Manufacturing, Rio Health, Eapro Global and Betterhood are very different businesses, but their fundraising tells a common story. Investors are backing companies that solve real-world problems, from faster medicine delivery to local ammunition production and better pain care.

Hughes Precision Manufacturing – Building defence manufacturing capacity

Hughes Precision Manufacturing has raised more than Rs. 250 crore to expand its ammunition manufacturing business. The company was incorporated in 2016 and is focused on small-caliber ammunition for defence, law enforcement and approved global customers.

Its latest funding will mainly support capacity expansion. As per the company announcement, Hughes plans to increase small-caliber ammunition capacity from about 80 million rounds to 220 million rounds. It also wants to enter medium-caliber ammunition manufacturing.

The company is led by Managing Director Sanjay Soni.

The aim is simple but important. India wants stronger local defence production, and Hughes wants to become a serious private-sector player in that space. Its competitors and peers include public-sector defence manufacturers and private defence firms such as Munitions India, Solar Industries and other ammunition suppliers.

Rio Health – Fast medicine delivery through WhatsApp

Rio Health has raised Rs. 43.08 crore in a pre-Series A round led by Version One Ventures. Existing investors Xeed Ventures, Good Capital and Amplify Partner also joined the round.

Founded by Ankur Agrawal and Amit Ahuja, Rio Health is building a quick-commerce platform for medicines and healthcare essentials.

The company lets customers order through WhatsApp and aims to deliver medicines and healthcare products in around 15 to 30 minutes. Its operating entity, Rapidsurge Innovations Private Limited, was incorporated in 2023.

The fresh money will be used for working capital, capital expenditure, business expansion and strengthening the company’s capital base.

Rio is entering a crowded but useful market. Competitors include Tata 1mg, Apollo 24/7, PharmEasy, Netmeds and local pharmacy delivery services. Its WhatsApp-first approach may help customers who do not want to download another app.

Eapro Global – Power backup and clean energy growth

Eapro Global has raised Rs. 40 crore in pre-IPO funding. The Roorkee-based company makes solar inverters, batteries and energy storage systems.

It was founded in 2012 by Jagdeep Chauhan, who is also its Founder and Managing Director.

The funding round included Aarth AIF Growth Fund, NAV Bharat Investment Opportunities Fund, VentureX Fund, Kyro India Opportunities Fund – I and the JK family office. The company is reportedly preparing for a possible FY28 IPO.

Eapro plans to use the funds to expand manufacturing capacity, improve technology and grow in India’s clean energy and power-backup market. This is practical money for a practical business. Homes, shops and factories need reliable power, and solar-plus-storage products are becoming more relevant as energy demand rises.

Its competitors include Luminous, Microtek, Livguard, Exide and other inverter, battery and solar equipment companies.

Betterhood – Preventing pain before it becomes serious

Betterhood has raised Rs. 11.5 crore in a seed round led by Sauce, with participation from existing investor Kairon Capital.

The brand was founded by Vikram Kadam and Neha Zade and launched in October 2024.

Betterhood focuses on preventive pain care. Its products cover posture support, back support, knee and wrist support, recovery products and other musculoskeletal health needs. In simple words, it wants people to take care of body pain early instead of waiting until it becomes a bigger daily problem.

As per ET, the startup had earlier raised Rs. 5 crore led by Kairon Capital. That money was meant for product development, team expansion and wider online and offline distribution.

Betterhood competes with brands such as Tynor, Vissco and other pain care, posture and wellness product companies. Its edge may come from combining products with education and physiotherapist-led awareness.

Conclusion with key takeaways

These four funding rounds show how broad India’s startup and growth-company market has become.

Hughes Precision is scaling defence manufacturing. Rio Health wants to make medicine delivery faster and simpler. Eapro Global is preparing for clean energy and power-backup demand. Betterhood is trying to build a new habit around early pain care.

For beginners tracking startup funding, the main lesson is clear. Investors are not just chasing flashy ideas. They are looking at capacity, trust, distribution, repeat demand and real customer problems.

References- PR Newswire, Newzchain, The Financial World, Deccan Founders

Disha, formerly known as Curelink, has raised around $5.3 million in a Series A funding round led by General Catalyst. The round also saw participation from existing investor Elevation Capital, along with Flamel Performing Creatives Private Limited.

The company is building an AI-powered health coaching platform for Indian users who need help with diet, fitness and chronic-care support. In simple words, Disha wants to make health guidance more regular, more personal and easier to access in everyday language.

What Disha does

Disha is the consumer health coaching product built by Curelink. Curelink was founded in 2021 by Aman Singla and Divyansh Jain.

The platform offers coaching support across areas like weight loss, PCOS, thyroid, diabetes, pregnancy, postpartum recovery and other lifestyle-linked health needs. It works in Hindi, English and Hinglish, which is important because many Indians are more comfortable asking health questions in mixed or local language.

Disha says it combines AI with clinical protocols and coaching support. The idea is not to replace doctors, but to help users stay consistent with daily habits such as food choices, workouts, follow-ups and small lifestyle changes.

Funding purpose

As per reports, Disha raised Rs. 43.88 crore in this Series A round. General Catalyst invested the largest amount, while Elevation Capital also joined the round.

The fresh capital is expected to be used for working capital, AI model development, technology improvement, business expansion and general corporate needs.

This makes sense for a health coaching platform. To grow responsibly, Disha needs stronger AI systems, better user experience, more condition-specific plans and reliable coaching workflows. Health guidance is sensitive, so accuracy and safety matter as much as scale.

Why this model matters

Many people start health plans with good energy but stop after a few days. The problem is not always lack of intention. Sometimes users need reminders, food suggestions, emotional support and practical guidance that fits their normal routine.

For example, a user managing PCOS may not only need a diet chart. She may need daily meal swaps, movement reminders, sleep advice and someone to explain what to do when cravings or fatigue hit. Disha is trying to make that support available more often through AI-led coaching.

Traction and business details

Disha claims more than 70 lakh sign-ups, around 3 lakh active users and over 1.4 crore messages exchanged on the platform. Its website also says the product is built on Curelink’s clinical experience and health data.

Reports also note that Disha’s revenue doubled to Rs. 4.91 crore in FY25 from Rs. 2.47 crore in FY24, while losses narrowed to Rs. 4.45 crore. These are still early-stage numbers, but they show that the company is moving from pure product-building toward a more serious business phase.

Competitors and market view

Disha competes in a growing healthtech space where users already see options from companies like Healthify, Fitterfly, Ultrahuman, Sugar.fit and other digital wellness and chronic-care platforms.

Its edge may come from language-first coaching, AI-led personalization and India-specific health behaviour. But the real test will be trust. Users will stay only if the advice feels useful, safe and practical.

Image Credit

Physioplus Healthcare has raised seed funding at a valuation of $800,000, giving the Jaipur-based healthtech startup fresh support for its next stage of growth. The round comes at a time when more Indians are becoming open to digital healthcare, home-based care, and structured rehabilitation services.

The startup is focused on physiotherapy, an area that often gets less attention than doctor consultations or medicine delivery. For many people, finding the right physiotherapist is still a slow process. Physioplus Healthcare wants to make that search easier, while also giving physiotherapists better digital tools to manage patients and treatment records.

What Physioplus Healthcare does

Physioplus Healthcare is a digital-first physiotherapy platform based in Jaipur. As per recent funding reports, the startup was founded in 2022 and its co-founders include Samit Saxena, Jaswant Singh, and Madhukar Pareek.

The company connects patients with certified physiotherapists and supports care areas such as chronic pain, sports injuries, post-surgery rehabilitation, and musculoskeletal problems. In simple terms, these are issues related to bones, muscles, joints, posture, and movement.

For example, someone recovering after knee surgery may need regular physiotherapy sessions, progress tracking, and exercise guidance. A platform like Physioplus can help that patient find a suitable physiotherapist and continue treatment in a more organized way.

Funding purpose and growth plan

The fresh seed investment is expected to help Physioplus Healthcare improve its technology platform, grow its physiotherapist network, and expand across India. The funding came from HBF Direct Limited, according to recent reports and company-linked updates.

This is important because physiotherapy is not just about booking one session. Good recovery usually needs assessment, follow-up, exercise plans, records, and regular monitoring. Physioplus is trying to bring these parts into one digital system.

The company’s wider aim appears to be building a more structured physiotherapy ecosystem where patients can discover care easily and physiotherapists can manage their work better.

Why this matters for patients

Physiotherapy is often needed after injuries, surgeries, long-term pain, or mobility problems. But many patients delay treatment because they do not know whom to visit, how often to go, or whether home care is available.

A digital platform can reduce some of this confusion. If done well, it can help patients find verified professionals, book care faster, and keep track of their recovery.

This is especially useful in India’s smaller cities, where access to specialist rehabilitation services may not be as smooth as in metro areas.

Competitors and market context

Physioplus Healthcare is not alone in this space. Other startups and healthtech companies are also working around physiotherapy, rehabilitation, and musculoskeletal care. Reports mention names such as FlexifyMe, Stance Health, and Rebee Health in the broader digital physiotherapy and rehab-tech market.

The competition shows that investors are watching this category more closely. Still, the market is early, and trust will matter a lot. Patients will not choose a physiotherapy platform only because it is digital. They will choose it if the care feels reliable, affordable, and consistent.

Ayati Devices has raised Rs. 15 crore in a Pre-Series A funding round led by Inflexor Ventures. The Bengaluru-based medtech startup will use the capital to scale its AI-driven diabetic foot diagnostics platform and expand its reach in India and global markets.

Ayati is working on a medical problem that often stays hidden until it becomes serious. Many diabetes patients slowly lose sensation in their feet. If nerve damage or poor blood flow is not caught early, a small wound can turn into an ulcer, infection or even amputation.

That is the gap Ayati Devices wants to solve. Its products help doctors screen diabetic foot complications faster, more objectively and closer to the patient.

What Ayati Devices Does

Ayati Devices builds diagnostic tools for diabetic foot complications and peripheral vascular disease. In simple words, its devices help doctors check whether a diabetes patient has nerve damage, poor blood circulation or weak tissue-level blood flow in the feet.

The company’s platform covers different parts of the diabetic foot diagnosis journey. Vibrasense is used for neuropathy screening. Neuropathy means nerve damage, and in diabetes patients, it can reduce the ability to feel pain, heat or pressure in the feet.

Vibrasense+T goes deeper by checking both large and small nerve fibre function. Vasosense is used to detect peripheral artery disease, which happens when blood flow to the limbs becomes poor. Angiocam focuses on tissue perfusion imaging, which helps doctors understand blood flow at the tissue level.

Ayati also offers the PODIA Trolley, a screening station designed around a pay-per-test model. This can be useful for clinics and hospitals that want to run diabetic foot screening without heavy upfront device investment.

Founders And Founding Year

Ayati Devices was founded in 2019 by Nishant Kathpal and Pankaj Inchulkar. The company has been incubated at IIT Bombay’s SINE, which supports technology-led startups coming out of research and innovation programs.

Nishant Kathpal is the founder and CEO of Ayati Devices. He has been closely associated with the development and commercial journey of its diabetic foot screening technology.

This founder background matters because medtech is not easy to build. A startup in this space must handle product engineering, clinical use, regulations, manufacturing and doctor trust at the same time.

Why The Rs. 15 Crore Funding Matters

The fresh funding will help Ayati Devices move from product availability to wider scale.

According to reports, the company plans to use the capital for Angiocam’s commercialization, go-to-market expansion in India and abroad, manufacturing and supply chain capacity, AI-enabled diagnostics R&D, regulatory approvals, intellectual property growth and team building.

That is a fairly broad plan, but it makes sense for a medical device company at this stage. Ayati already has products in the market. Now it needs to make them easier to access, easier to deploy and stronger from a technology and regulatory point of view.

For example, a hospital may want neuropathy screening, vascular testing and tissue perfusion imaging in one connected workflow. If Ayati can offer this as a practical platform, it can become more useful than a single standalone device.

The Main Aim Of The Funding

The main aim of the funding is to make diabetic foot diagnostics more accessible and scalable.

Many advanced diagnostic tools are usually found in large hospitals or specialist centres. But diabetic foot risks do not begin only when a patient reaches a big hospital. They often begin quietly at home, in small clinics or during regular diabetes check-ups.

Ayati wants its tools to work in hospitals, primary care clinics and community screening programs. That matters in India, where many patients may not visit specialists until symptoms become serious.

A simple example explains the need. A patient with long-term diabetes may not feel a small injury under the foot because of nerve damage. If a clinic can detect neuropathy early, the doctor can advise better footwear, regular monitoring, sugar control and specialist care before the condition worsens.

That early diagnosis can reduce pain, cost and risk for the patient.

Current Reach And Market Opportunity

Ayati Devices has deployed more than 10,000 devices across over 30 countries. The company also has regulatory clearances in major markets, including India, the US, Europe, Sri Lanka, Malaysia and the UAE.

Ayati’s addressable market is around US$ 15 billion globally and US$ 1.4 billion in India. This includes diabetic neuropathy, peripheral vascular disease and tissue perfusion imaging.

These numbers show why investors are interested. Diabetes is a large and growing healthcare challenge, and foot-related complications can become expensive and life-changing if missed early.

Products like Ayati’s sit at the meeting point of preventive care, medical devices and AI-supported diagnostics.

Why AI Matters In This Space

AI in healthcare can sound like a buzzword, but in diagnostics it can be practical when used carefully.

In Ayati’s case, AI-enabled diagnostics can help doctors interpret screening data more consistently. It may support faster reports, better risk scoring and easier follow-up for patients.

This does not mean AI replaces doctors. It means doctors can get clearer measurements and decision support. In busy clinics, that can save time and improve screening quality.

For diabetic foot care, this is useful because many patients need regular monitoring, not just one-time testing.

Competitors And Similar Companies

Ayati Devices works in the broader Indian medtech and digital diagnostics space. Its direct competition may include global device makers offering neuropathy, vascular and foot pressure assessment tools.

In India, companies such as Remidio, Niramai, SigTuple and Tricog operate in nearby healthtech categories, though they do not all focus on diabetic foot diagnostics. These startups show how Indian medtech is moving toward early detection, portable devices and smarter clinical workflows.

Ayati’s sharper focus is diabetic foot care. That focus could help it build deep expertise in one serious disease area instead of spreading itself too thin.

Challenges Ahead

Ayati has a strong opportunity, but scaling medical devices is never simple.

Hospitals need training, service support and proof that devices work reliably in real clinical settings. International expansion also brings more regulatory work, distributor management and after-sales support.

Affordability will be another key factor. If Ayati wants to reach smaller clinics and community programs, its solutions must remain practical in cost as well as performance.

The company’s pay-per-test model could help here, especially for centres that want screening access without large upfront spending.

Conclusion With Key Takeaways

Ayati Devices’ Rs. 15 crore Pre-Series A round is a meaningful step for India’s medtech ecosystem. The company is working on a real healthcare problem that affects millions of diabetes patients but often gets less attention than it deserves.

With support from Inflexor Ventures, Ayati now has more capital to commercialize Angiocam, expand its diagnostic platform, grow internationally and strengthen its AI-led product roadmap.

Key takeaways –

• Ayati Devices has raised Rs. 15 crore in Pre-Series A funding led by Inflexor Ventures.
• The startup was founded in 2019 by Nishant Kathpal and Pankaj Inchulkar.
• It builds diagnostic tools for diabetic foot complications and peripheral vascular disease.
• The funding will support Angiocam commercialization, global expansion, manufacturing, R&D and regulatory approvals.
• Ayati has deployed more than 10,000 devices across over 30 countries.

Facts Input- Pharmabiz

Immuneel Therapeutics has raised over Rs. 100 crore in a Series B funding round, giving India’s advanced cancer treatment space another important moment. The Bengaluru-based biotech startup is working in cell and gene therapy, a field that is still young in India but could become highly important for patients with difficult-to-treat cancers.

The round was led by new investors including Singularity AMC and Rainmatter by Zerodha, along with participation from several high-net-worth individuals. Existing backers such as Kiran Mazumdar-Shaw, Eight Roads Ventures and F-Prime Capital also joined the round.

Immuneel is trying to build a serious healthcare platform from India for CAR-T therapy, a complex treatment that uses a patient’s own immune cells to fight cancer. For a country where advanced cancer care is often expensive and limited to a few hospitals, this funding could help expand access, manufacturing and research.

What Immuneel Therapeutics Does

Immuneel Therapeutics works on cell and gene therapies, with a major focus on CAR-T therapy. In simple words, CAR-T therapy takes certain immune cells from a patient, modifies them in a lab, and sends them back into the body to identify and attack cancer cells. This is very different from regular chemotherapy. Chemotherapy attacks fast-growing cells, which can include cancer cells as well as healthy cells. CAR-T therapy is more targeted, though it is also complex, expensive and needs strong medical infrastructure.

Immuneel’s main focus is blood cancers such as lymphoma and leukemia. Its product Qartemi is being commercialized for Non-Hodgkin Lymphoma, and the company is also working on a wider pipeline of next-generation cell and gene therapies.

Founders And Company Background

Immuneel Therapeutics was founded in 2018-2019, with public profiles mentioning both years across different sources. Its key co-founders are Kiran Mazumdar-Shaw, founder and executive chairperson of Biocon; Dr. Siddhartha Mukherjee, oncologist, author and cancer researcher; and Dr. Kush M Parmar, physician-investor and managing partner at 5AM Ventures.

That founding team gives the company a mix of biotech business experience, clinical research depth and global life sciences investing knowledge. This matters because cell therapy is not a simple consumer-tech business. It needs scientific credibility, hospital partnerships, regulatory discipline, manufacturing quality and patient trust.

The company is currently led by CEO Amit Mookim, who has said the latest funding will help Immuneel move into its next phase after Qartemi’s commercial launch.

How The New Funding Will Be Used

Immuneel plans to use the fresh capital for four broad goals.

1. First, it wants to expand its Good Manufacturing Practice manufacturing capacity. GMP is a quality system used in pharma and biotech manufacturing to make sure therapies are produced safely and consistently.
2. Second, the company will support the commercial rollout of Qartemi. This is important because launching a therapy is only one part of the journey. Patients, hospitals, doctors and payers also need access, awareness and affordability support.
3. Third, Immuneel will invest in research and development for newer cell and gene therapy programs. This could help it move beyond one product and build a stronger biotech pipeline.
4. Fourth, the company is looking at international expansion across Asia-Pacific and the Middle East. If executed well, this could position Immuneel as an India-built advanced therapy company with global ambitions.

Why This Funding Matters For India

India has strong doctors, hospitals and scientific talent, but advanced therapies like CAR-T have historically been costly and difficult to access. Imported CAR-T treatments in global markets can be extremely expensive, often putting them beyond the reach of many Indian families.

Immuneel’s larger promise is affordability with quality. If India can manufacture and deliver such therapies locally, treatment costs may become more manageable compared with Western markets. That does not mean CAR-T will suddenly become cheap, but local production can make a meaningful difference.

A practical example makes this easier to understand. If a patient needs a highly specialized therapy that must be imported or processed abroad, costs and timelines rise sharply. But if the therapy can be manufactured through a compliant facility in India and delivered through local hospital networks, the care pathway can become faster and potentially more affordable.

The Bigger Market Opportunity

Cancer treatment is moving toward personalization. Instead of treating every patient in the same way, doctors increasingly look at cancer type, genetic markers, immune response and treatment history. CAR-T fits into this shift because it uses the patient’s own cells as part of the treatment.

For investors, this makes Immuneel part of a larger health-tech and biotech trend. India has already seen growth in digital health, diagnostics, medical devices and pharma manufacturing. Cell and gene therapy could become the next serious frontier, though it will require patience and heavy capital.

Unlike mobile apps or quick-commerce startups, biotech companies usually take longer to scale. Clinical trials, approvals, hospital adoption and safety monitoring all take time. That makes funding rounds like this important because the company needs long-term capital before the business can mature fully.

Competitors And Market Landscape

Immuneel operates in a specialized space, so its competition is not like a normal startup market with dozens of similar apps. Its competitors and comparable players include Indian and global companies working on CAR-T, oncology, cell therapy and advanced cancer treatments.

In India, ImmunoACT is an important name because it developed NexCAR19, India’s first indigenous CAR-T cell therapy. Globally, companies such as Novartis, Gilead’s Kite Pharma, Bristol Myers Squibb and Legend Biotech are known for CAR-T and cell therapy products.

Immuneel’s edge will depend on affordability, manufacturing quality, clinical results, doctor adoption, hospital partnerships and how quickly it can expand beyond one therapy. In advanced healthcare, trust is built slowly. Strong science matters more than hype.

What Patients And Families Should Understand

CAR-T therapy sounds exciting, but it is not a general cancer cure for everyone. It is used for specific cancer types and usually after doctors assess whether the patient is eligible. It can also have side effects and requires close hospital supervision.

So, while Immuneel’s funding is good news for India’s biotech ecosystem, patients should always speak to qualified oncologists before considering any treatment. Startup funding does not replace medical advice, and treatment decisions should be based on diagnosis, stage, prior therapy, clinical suitability and doctor guidance.

Conclusion With Key Takeaways

Immuneel Therapeutics’ over Rs. 100 crore Series B round is a major development for India’s advanced cancer therapy space. The funding strengthens the company’s plan to scale CAR-T manufacturing, expand Qartemi’s commercial rollout, build its research pipeline and explore global markets.

Key takeaways

• Immuneel Therapeutics has raised over Rs. 100 crore in Series B funding.
• The round included Singularity AMC, Rainmatter by Zerodha, HNIs and existing investors such as Kiran Mazumdar-Shaw, Eight Roads Ventures and F-Prime Capital.
• The company is focused on CAR-T cell therapy, mainly for blood cancers such as lymphoma and leukemia.
• Immuneel was co-founded by Kiran Mazumdar-Shaw, Dr. Siddhartha Mukherjee and Dr. Kush M Parmar.

The funding could help India build more affordable, locally manufactured advanced cancer treatment options.

Facts Input- MC